Lumasiran (OXLUMO)
Primary Hyperoxaluria Type 1
ApprovedCommercial
Key Facts
About Alnylam Pharmaceuticals
Founded in 2002, Alnylam Pharmaceuticals is a leading biopharmaceutical company that pioneered the RNAi therapeutics revolution. The company leverages RNA interference technology to selectively silence genes that cause or contribute to disease, offering a fundamentally different approach to treating genetic disorders. With multiple approved therapies and a strong pipeline focused on rare diseases, Alnylam has established itself as the definitive leader in RNAi therapeutics with global reach and operations.
View full company profile